Table 1.
Sample characteristics
| Attribute | n | Mean ± SD |
|---|---|---|
| Sample | ||
| Full | 101 | – |
| After exclusion of screening failures | 97 | – |
| After exclusion of subjects with lacking or noisy fMRI sequences | 79 | – |
| After exclusion of subjects with lacking fitness data | 58 | – |
| Age (years) | 97 | 37.35 ± 12.20 |
| Sex | – | |
| Male | 62 (63.9%) | – |
| Female | 35 (36.1%) | – |
| Site | ||
| Munich | 72 (74.2%) | – |
| Mannheim | 25 (25.8%) | – |
| Chlorpromazine equivalents (CPZ) | 97 | 372.11 ± 245.74 |
| Years of education | 97 | 14.48 ± 4.14 |
| Disorder duration (years) | 97 | 9.29 ± 9.24 |
| Body-mass-index (BMI) | 97 | 28.30 ± 5.31 |
Important sample characteristics of the whole sample are listed. All numbers relate to the study sample after exclusion of screening failures. Screening failures reflect cases that were removed due to inclusion and exclusion criteria. Data from other sub-samples are neglected because they are fairly similar